Announcement

Collapse
No announcement yet.

J Pediatric Infect Dis Soc . Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • J Pediatric Infect Dis Soc . Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine


    J Pediatric Infect Dis Soc


    . 2021 Jul 28;piab060.
    doi: 10.1093/jpids/piab060. Online ahead of print.
    Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine


    Eric Tano 1 , Stephanie San Martin 1 , Stephen Girgis 1 , Yadira Martinez-Fernandez 2 , Carolina Sanchez Vegas 3



    Affiliations

    Abstract

    On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/pres...-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.

    Keywords: BNT162b2; COVID-19 vaccine; myocarditis; pericarditis.

Working...
X